Skip to main content
Top
Published in: Pediatric Radiology 3/2004

01-03-2004 | Minisymposium

Issues specific to implementing PET–CT for pediatric oncology: what we have learned along the way

Author: Sue C. Kaste

Published in: Pediatric Radiology | Issue 3/2004

Login to get access

Abstract

In parallel with the expansion of PET imaging to pediatric patients has been the technological development of merging state-of-the-art cross-sectional anatomic information (CT) with functional imaging (PET) into a single modality: PET–CT. Attending to the clinical, scheduling, and medical needs that are unique to imaging children and adolescents can be a challenge, particularly when instituting a single new modality. When that modality bridges two unique, previously independent methods—often previously located in two separate departmental divisions—the details and logistics required to set up a smoothly functioning process can be particularly difficult. This paper focuses on our experience in implementing PET–CT in a tertiary pediatric referral center.
Literature
1.
go back to reference Antoch G, Freudenberg LS, Strattus J, et al (2002) Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR 179:1555–1560 Antoch G, Freudenberg LS, Strattus J, et al (2002) Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR 179:1555–1560
2.
go back to reference Dizendorf EV, Treyer V, von Schulthess GK, et al (2002) Application of oral contrast media in coregistered positron emission tomography-CT. AJR 179:477–481 Dizendorf EV, Treyer V, von Schulthess GK, et al (2002) Application of oral contrast media in coregistered positron emission tomography-CT. AJR 179:477–481
3.
go back to reference Holbrook S (2002) 18-FDG PET whole-body imaging: developing an oncology protocol. Adv Imag Radiat Ther 15:9 Holbrook S (2002) 18-FDG PET whole-body imaging: developing an oncology protocol. Adv Imag Radiat Ther 15:9
4.
go back to reference Goerres GW, von Schulthess GK, Hany TF (2002) Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR 179:1337-1343 Goerres GW, von Schulthess GK, Hany TF (2002) Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR 179:1337-1343
5.
go back to reference Kostakiglu L, Agress H, Goldsmith SJ (2003) Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23:315–340PubMed Kostakiglu L, Agress H, Goldsmith SJ (2003) Clinical role of FDG PET in evaluation of cancer patients. Radiographics 23:315–340PubMed
6.
go back to reference Daldrup-Link HE, Franzius C, Link TM, et al (2001) Whole-body imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR 177:229–236PubMed Daldrup-Link HE, Franzius C, Link TM, et al (2001) Whole-body imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR 177:229–236PubMed
7.
go back to reference Hawkins DS, Rajendran JG, Conrad EU III, et al (2002) Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 94:3277–3284CrossRefPubMed Hawkins DS, Rajendran JG, Conrad EU III, et al (2002) Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 94:3277–3284CrossRefPubMed
8.
go back to reference Brenner W, Bohuslavizki KH, Eary JF (2003) PET imaging of osteosarcoma. J Nucl Med 44:930–942PubMed Brenner W, Bohuslavizki KH, Eary JF (2003) PET imaging of osteosarcoma. J Nucl Med 44:930–942PubMed
9.
go back to reference Bredella MA, Caputo GR, Steinback LS (2002) Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR 179:1145–1150PubMed Bredella MA, Caputo GR, Steinback LS (2002) Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR 179:1145–1150PubMed
10.
go back to reference Franzius C, Sciuk J, Daldrup-Link HE, et al (2000) PDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305–1311PubMed Franzius C, Sciuk J, Daldrup-Link HE, et al (2000) PDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305–1311PubMed
11.
go back to reference Shulkin BL, Mitchell DSA, Ungar DR, et al (1995) Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-d-glucose PET studies. Radiology 194:495–500PubMed Shulkin BL, Mitchell DSA, Ungar DR, et al (1995) Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-d-glucose PET studies. Radiology 194:495–500PubMed
12.
go back to reference Shulkin BL, Hutchinson RJ, Castle VP, et al (1996) Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-doexy-d-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199:743–750PubMed Shulkin BL, Hutchinson RJ, Castle VP, et al (1996) Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-doexy-d-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199:743–750PubMed
13.
go back to reference Kushner BH, Yeung HWD, Larson SM, et al (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up patients. J Clin Oncol 19:3397–3405PubMed Kushner BH, Yeung HWD, Larson SM, et al (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up patients. J Clin Oncol 19:3397–3405PubMed
14.
go back to reference Scharko AM, Perlman SC, Pyzalski RW, et al (2003) Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 362:959–961CrossRefPubMed Scharko AM, Perlman SC, Pyzalski RW, et al (2003) Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 362:959–961CrossRefPubMed
15.
go back to reference Iyengar S, Chin B, Margolick JB, et al (2003) Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 362:945–950CrossRefPubMed Iyengar S, Chin B, Margolick JB, et al (2003) Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet 362:945–950CrossRefPubMed
Metadata
Title
Issues specific to implementing PET–CT for pediatric oncology: what we have learned along the way
Author
Sue C. Kaste
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
Pediatric Radiology / Issue 3/2004
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-003-1111-6

Other articles of this Issue 3/2004

Pediatric Radiology 3/2004 Go to the issue